Melanotan I Peptide: The Complete Guide - Uses, Mechanism, Dosing, Safety & Research

Quick Facts

What Melanotan I Does & How It Works

What It Does , Functional Outcomes

• Stimulates skin tanning by driving eumelanin production in melanocytes , without requiring UV exposure to trigger the process
• Increases the skin's natural resistance to UV-induced damage, reducing sunburn cell formation and the mutagenic burden from UV radiation
• Significantly increases pain-free sun exposure time in people with erythropoietic protoporphyria, the FDA-approved indication
• Reduces UV-triggered inflammatory responses in skin tissue through MC1R activation on peripheral immune cells
• Enhances cellular DNA repair capacity via upregulation of nucleotide excision repair pathways
• Produces tanning that persists for more than three weeks after dosing ends, based on Phase 1 sunlight study data

How It Works , Mechanism of Action

MC1R Activation and the Melanin Production Cascade (Evidence: Human and animal)

MT-1 binds to the melanocortin-1 receptor (MC1R) , a G protein-coupled receptor present primarily on melanocytes, the pigment-producing cells in skin. This binding triggers a signaling chain that starts by raising intracellular cAMP (cyclic AMP, a chemical messenger inside cells). Elevated cAMP then activates PKA (Protein Kinase A, an enzyme that relays the signal further along the chain). PKA phosphorylates CREB (a protein that switches on specific genes), which in turn upregulates MITF (the master transcription factor , essentially the main on-switch for melanin production). MITF drives expression of tyrosinase, the rate-limiting enzyme in eumelanin synthesis.

Eumelanin vs. Pheomelanin: Why the Pigment Type Matters (Evidence: Human and animal)

MC1R activation by MT-1 specifically drives eumelanin production rather than pheomelanin. Eumelanin is brown-to-black in color and is genuinely photoprotective , it absorbs UV radiation across a broad spectrum. Pheomelanin, by contrast, is red-to-yellow and may actually sensitize skin to UV damage by generating reactive oxygen species upon UV exposure. Individuals with loss-of-function MC1R variants , typically fair-skinned, red-haired phenotypes , produce predominantly pheomelanin and have impaired natural UV protection. MT-1's mechanism targets this specific switch.

Nucleotide Excision Repair (NER) Upregulation (Evidence: Animal and in vitro)

The cAMP signal generated through MC1R activation also upregulates nucleotide excision repair (NER) , the cellular machinery responsible for finding and removing UV-induced DNA damage. The specific lesions targeted are cyclobutene pyrimidine dimers (CPDs, damaged DNA sections formed when UV-B radiation fuses adjacent DNA bases together). CPDs are the primary mutagenic lesions implicated in skin cancer initiation. Enhanced NER capacity reduces this mutagenic burden in melanocytes and keratinocytes, representing a separate photoprotective mechanism operating alongside physical UV absorption by melanin.

Anti-Inflammatory Signaling via Peripheral MC1R (Evidence: Animal and early human)

MC1R is not only expressed on melanocytes. It is also present on macrophages, monocytes, T-cells, keratinocytes, and fibroblasts throughout peripheral tissue. MT-1 activation of MC1R on these immune cells suppresses pro-inflammatory cytokines including IL-1, inhibits neutrophil migration, and reduces inflammatory signaling. Studies using MC1R-deficient mouse models confirmed that these anti-inflammatory effects are absent without functional MC1R , establishing the receptor's necessary role rather than treating these observations as coincidental.

Melanotan I Molecular Profile

Structure reference: View on PubChem , Publishing team: retrieve 2D structure image from this link.

The two structural modifications are worth understanding because they are not arbitrary. Native alpha-MSH has a half-life of only minutes in circulation, making it pharmacologically impractical. Replacing methionine at position 4 with norleucine eliminates a major oxidative vulnerability. Methionine is easily oxidized in the body, and norleucine substitution removes that weak point entirely. Replacing L-phenylalanine at position 7 with its D-amino acid mirror image makes the peptide far more resistant to the enzymes that would otherwise break it down. D-amino acid substitutions resist proteolytic cleavage because peptidases preferentially cleave L-amino acid configurations. The result is a compound that maintains the natural peptide's 13-amino acid linear structure and MC1R selectivity but survives long enough in circulation to actually do something useful.

Melanotan I Uses & Benefits

Erythropoietic Protoporphyria (EPP)

EPP is a rare, inherited metabolic disorder caused by a deficiency of the enzyme ferrochelatase. That deficiency leads to accumulation of protoporphyrin IX in red blood cells. When affected individuals are exposed to UV or visible light, this accumulated compound generates a phototoxic reaction , intense burning pain, skin damage, and scarring that can persist for days. The condition severely limits patients' ability to be outdoors and profoundly affects quality of life. MT-1 addresses this by pre-loading melanin to act as a natural broadband UV absorber, reducing the amount of light that reaches and activates the accumulated protoporphyrin. The evidence base for this application is the strongest available for any melanocortin peptide , three Phase 3 randomized controlled trials with 244 adult participants, forming the foundation for FDA approval of Scenesse in 2019. (Evidence: Strong , Langendonk et al., 2015, NEJM)

UV Photoprotection and Sunless Tanning

Outside the EPP population, the most extensively researched and practically pursued application of MT-1 is UV photoprotection , particularly for individuals with fair skin, photosensitive conditions, or significant UV exposure risk. The mechanism here is the same as in EPP: eumelanin synthesis via MC1R activation provides a physical UV-absorbing layer in skin that is present before UV exposure rather than built in response to it. Phase 1 research showed approximately 50% less sun exposure required to achieve equivalent tanning compared to controls, with tanning persisting more than three weeks post-dosing. Research-use protocols in this context are studied for reducing UV sensitivity in skin types I and II. (Evidence: Moderate , Phase 1 human data)

Polymorphic Light Eruption (PLE)

Polymorphic light eruption is one of the most common UV-related skin conditions , an inflammatory rash triggered by UV exposure, particularly in spring and early summer when the skin has not yet built seasonal tolerance. The proposed mechanism for MT-1 in PLE parallels EPP: pre-loading melanin before UV season reduces the UV dose reaching the skin on early-season exposures, potentially preventing the triggering of the PLE inflammatory cascade. Phase 3 trials in PLE have been conducted, representing a significant expansion of the clinical evidence base beyond the EPP approval. Full peer-reviewed results are not comprehensively available in the published literature as of this guide's update date. (Evidence: Moderate , Phase 3 trials conducted; full published results limited)

Reduction of Photodynamic Therapy (PDT) Phototoxicity

Photodynamic therapy uses light-activated agents to treat certain skin conditions and cancers, but it generates a phototoxic reaction that is one of the procedure's more painful side effects. Phase 2 trial data from approximately 2004 showed that MT-1 reduced phototoxicity following PDT, improved sunlight tolerance in treated subjects, and was associated with improved mood as a secondary finding. The mechanism is consistent with MT-1's photoprotective and anti-inflammatory effects via MC1R. Detailed peer-reviewed results from these Phase 2 trials are limited in publicly available literature. (Evidence: Moderate , Phase 2 human data)

Anti-Inflammatory and Skin Repair Applications

MT-1's anti-inflammatory effects via peripheral MC1R activation extend its potential applications beyond pigmentation and UV protection. MC1R is expressed on macrophages, monocytes, T-cells, keratinocytes, and fibroblasts, and its activation suppresses pro-inflammatory cytokines and reduces inflammatory cascades in skin tissue. Research has also identified MT-1's involvement in matrix metalloproteinase (MMP) modulation , MMPs are enzymes that break down and remodel the structural scaffold between cells (the extracellular matrix). MT-1 appears to upregulate MMP-1, MMP-2, and MMP-8 while downregulating their tissue inhibitors (TIMPs, proteins that normally block MMP activity) , suggesting potential relevance in extracellular matrix remodeling and fibrosis research. These applications are less clinically developed than the photoprotection indications. (Evidence: Preliminary , animal and in vitro data)

Where This Melanotan I Guide Comes From

Melanotan I Results & Timelines

MT-1 has something unusual for a research peptide: a documented clinical timeline from controlled Phase 1 studies rather than only forum-aggregated user reports. The timelines below draw from both published research and real-world protocol data tracked inside the MyPeptidePal Knowledge Base.

Skin Tanning and Pigmentation

• Days 3-7: Visible skin darkening typically first observed in Phase 1 research studies using daily subcutaneous dosing; onset depends on baseline skin type, MC1R genotype, and individual melanocyte responsiveness
• Days 7-10: Progressive tanning continues through standard Phase 1 study periods; more pronounced in skin types II and III compared to type I
• Post-dosing (weeks 1-3+): Phase 1 sunlight study data showed tanning persisting for more than three weeks after dosing ended , a clinically notable sustained effect
• Non-responders: Phase 1 data documented at least one subject with zero pigmentation response; MC1R polymorphism is the most likely explanation

UV Protection and Sunburn Reduction

• Days 1-7: Photoprotective eumelanin accumulation begins in parallel with visible tanning; functional UV protection increases progressively with melanin density
• Days 7-14: Phase 1 UV-B synergy data showed 47% reduction in sunburn cells with approximately 10 days of daily dosing combined with UV-B exposure
• Weeks 2-3: In EPP patients using the Scenesse implant, meaningful increases in pain-free sun tolerance are typically observed within the first treatment cycle as melanin levels build

Anti-Inflammatory Effects

• Week 1-2: Anti-inflammatory effects via MC1R on peripheral immune cells are mechanistically coupled to receptor activation rather than melanin accumulation , meaning the onset may parallel pigmentation onset, though direct timeline data in non-EPP populations is limited
• Week 2-4: EPP patients report reduced phototoxic pain episodes with progressive melanin building; whether the anti-inflammatory mechanism contributes independently of photoprotection is not clearly delineated in published data

How to Administer Melanotan I

Subcutaneous Injection (SubQ)

Subcutaneous injection is the primary documented route for research-use Melanotan I and the route used in all Phase 1 and Phase 2 clinical studies. The 1997 Phase 1 pharmacokinetic study confirmed complete SubQ bioavailability , the full dose reaches systemic circulation without the first-pass degradation that limits oral delivery. Phase 1 studies used abdominal and other standard subcutaneous sites with consistent results. SubQ injection delivers the compound into the fatty tissue beneath the skin rather than into muscle.

Intramuscular Injection (IM)

Intramuscular injection is not a standard route for MT-1 in published research. The Phase 1 and Phase 2 trial programs used subcutaneous administration throughout. IM injection is not documented as offering any pharmacokinetic advantage for this compound, and it is not a route commonly used in research-use protocols based on available documentation.

Oral

Oral administration is not a viable route for Melanotan I. The 1997 Phase 1 pharmacokinetic study directly evaluated oral delivery and confirmed substantially inferior bioavailability compared to subcutaneous injection , consistent with the gastric acid and enzymatic degradation that affects most peptides when swallowed. Despite the structural modifications (norleucine and D-phenylalanine substitutions) that provide proteolytic resistance in the body, gastric conditions remain too harsh for meaningful oral absorption. No oral formulation of MT-1 has been developed or studied for clinical use.

Subcutaneous Implant (FDA-Approved EPP Formulation)

The approved Scenesse formulation is a 16 mg subcutaneous implant placed approximately every two months, designed to release the compound slowly over roughly 30 days. This slow-release depot approach was developed specifically because MT-1's half-life of 0.8-1.7 hours makes sustained systemic levels impossible to maintain with standard daily injections. The implant is placed by a healthcare provider under the REMS program , it is not self-administered. The implant route is specific to the EPP indication and the approved pharmaceutical product.

Melanotan I Dosage & Cycle Length

Understanding how MT-1 has been dosed across its research history requires separating two very different contexts: the FDA-approved Scenesse implant used for EPP, and the injection-based protocols studied in Phase 1 and Phase 2 trials , as well as what appears in real-world research-use protocols. These are not interchangeable, and the numbers look quite different depending on which context you are reading about.

Overall dosing range: Published Phase 1 pharmacokinetic research used doses spanning 0.08 to 0.21 mg/kg per subcutaneous injection across 10 escalating doses. Phase 1 UV-B synergy and photoprotection work used 0.08 mg/kg daily. Phase 2 photoprotection studies used approximately 0.16 mg/kg. The FDA-approved EPP formulation is a fixed 16 mg subcutaneous implant per cycle.

How the goal shifts where you land:

• Low end of range (0.08 mg/kg): Used in early Phase 1 pharmacokinetic work and the UV-B synergy study; sufficient to observe tanning and sunburn cell reduction in responsive individuals
• Mid range: Represents the commonly studied dose in Phase 1 tanning and photoprotection work , the range where consistent tanning responses were documented across subjects
• High end of range (0.16-0.21 mg/kg): Used across Phase 1 pharmacokinetic escalation and Phase 2 photoprotection studies; associated with approximately 50% reduction in sunburn cells at skin types I/II (evidence grade: Moderate , Phase 2 human data)
• 16 mg implant (Scenesse): The approved EPP formulation , a fixed dose administered as a slow-release depot implant by a healthcare provider

Frequency: Phase 1 research studies used daily subcutaneous injection protocols over 10-day periods. The FDA-approved Scenesse implant is placed approximately every two months, with each implant releasing the compound over roughly 30 days, creating a monthly steady-state window of coverage.

Cycle length: Phase 1 injection studies used 10-day dosing periods. In EPP clinical practice, Scenesse implants are placed repeatedly across spring and summer months to provide coverage during peak UV exposure seasons. Research-use injection protocols outside the EPP context vary significantly , no standardized cycle length has been established in published literature for non-EPP applications.

Loading protocols: No formal loading protocol has been documented in published research for MT-1. Phase 1 studies used consistent daily dosing throughout the study period rather than a front-loaded approach.

Melanotan I Vial Sizes, Costs & Quality

Common vial sizes: Research-grade Melanotan I is typically available in 10 mg vials. Some suppliers offer smaller 5 mg quantities, though 10 mg is the more standard size at current market availability.

Typical cost range: $60-$120 per 10 mg vial for U.S.-manufactured research-grade peptides at current market pricing , varies by supplier, vial size, and purity certification level

Storage , lyophilized (dry powder):

• Temperature: Refrigerate at 2-8 degrees C; avoid room temperature storage for extended periods
• Shelf life: Approximately 12-24 months when stored sealed and refrigerated; freeze for long-term storage beyond this window
• Light sensitivity: Protect from light , store in opaque or darkened container

Storage , reconstituted (in solution):

• Temperature: Requires refrigeration at 2-8 degrees C after reconstitution
• Use window: Typically 28-30 days once reconstituted when stored correctly and handled carefully

Normal appearance after reconstitution: Melanotan I should dissolve into a clear, colorless to very slightly pale solution. This peptide dissolves cleanly under standard reconstitution conditions. Any significant cloudiness, visible particulates, or discoloration after reconstitution is not expected and should be treated as a quality concern.

Signs of degradation: Heavy cloudiness that does not clear, visible floating particles or chunks, discoloration (yellowing or browning of the solution), or an unusual odor. Degraded peptide should not be used.

Quality Considerations

Melanotan I has a structural vulnerability that makes quality especially relevant: the Position 4 modification , substituting norleucine for methionine , exists precisely because methionine is prone to oxidative degradation in the body. In a poorly manufactured or improperly handled batch, oxidative damage during synthesis or storage can undermine this protection entirely, leaving you with a compound that has begun to degrade before it ever reaches the target receptor. When a vial is priced well below market norms, that gap typically reflects shortcuts in purification, incomplete quality testing, or overseas manufacturing without independent verification. A lot of what circulates online comes from facilities with no documented chain of custody and no third-party HPLC or mass spectrometry testing , meaning the buyer has no practical way to confirm what is in the vial, what concentration it actually is, or whether the structural modifications are intact. U.S.-manufactured research peptides come with traceable manufacturing standards, documented synthesis processes, and verifiable certificates of analysis, which is the closest thing to accountability the research-grade market currently offers.

Melanotan I Side Effects & Safety

Side Effect Spectrum

The side effect profile for MT-1 in published clinical research is notably contained relative to many research peptides. Phase 1 studies reported GI upset and flushing as the consistent findings. Phase 3 EPP trials added mild hyperpigmentation (33% of subjects) and nevi formation (4% vs. 2% placebo) to the picture, though no increase in melanoma incidence was observed across the trial program.

Contraindications

• Active malignancy or history of melanoma: MC1R activation stimulates melanocyte activity; while no increase in melanoma was observed in Phase 3 EPP trials, use in individuals with active malignancy or a personal or family history of melanoma is not supported by available safety data and is generally avoided in clinical practice
• Pregnancy and breastfeeding: Insufficient safety data; not recommended without direct medical supervision
• Pediatric populations: Not studied in pediatric populations; not appropriate outside of medical supervision
• Concurrent use of photosensitizing medications: The combination of MT-1's melanocyte-stimulating effects with photosensitizing drugs introduces unpredictable UV reactivity; insufficient data to confirm safety of this combination

Populations Where Caution Is Warranted

• Pregnancy and breastfeeding: Insufficient safety data; use is not recommended without medical supervision
• Pediatric use: Not studied in pediatric populations; not appropriate without medical supervision
• Individuals with numerous or atypical moles (dysplastic nevi): The nevi formation signal in Phase 3 data , 4% vs. 2% placebo , warrants heightened dermatological surveillance in anyone with a pre-existing history of atypical nevi or a strong family history of melanoma
• Individuals with loss-of-function MC1R variants: Phase 1 data documented at least one confirmed non-responder, most likely attributable to MC1R polymorphism; this is not a safety contraindication, but response may be absent or substantially reduced

Red Flags , Stop Use and Seek Medical Attention If:

• New or rapidly changing moles appear during or after a protocol, particularly any lesion with asymmetry, irregular borders, multiple colors, or diameter greater than 6 mm
• Significant systemic allergic reaction , hives, difficulty breathing, throat tightening, or pronounced swelling at the injection site
• Unexplained neurological symptoms such as sudden severe headache, visual changes, or confusion
• Severe gastrointestinal symptoms that persist beyond the first few days of dosing

Drug and Compound Interactions

No formal drug-drug interaction studies for Melanotan I have been published in the available literature. Theoretical interaction concerns center on compounds that modulate melanocyte activity, affect immune signaling, or alter pigmentation pathways. The combination of MT-1 with other melanocortin peptides , including Melanotan II , has not been studied, and stacking melanocortin agonists introduces unpredictable receptor saturation dynamics. Individuals taking immunosuppressive therapies should note that MC1R has documented immune-modulatory effects, though no specific interaction data exist.

Melanotan I Research & Studies

MT-1 has something most research peptides never achieve: a completed Phase 3 clinical trial program and an FDA-approved indication. That changes the nature of what "the research shows" means for this compound. There is published human clinical data, and it is more substantial than anything available for the vast majority of compounds discussed in peptide research circles. Here is what the evidence actually says.

Pharmacokinetics & Metabolism

Absorption & Bioavailability The 1997 Phase 1 pharmacokinetic study (Dorr et al.) established the core pharmacokinetic profile across three routes , subcutaneous, intravenous, and oral. Subcutaneous bioavailability was confirmed as complete, meaning the SubQ route delivers the full dose to systemic circulation without significant first-pass loss. Oral bioavailability was substantially inferior, consistent with the peptide degradation expected in the gastrointestinal environment.

Distribution MT-1 does not readily cross the blood-brain barrier. Its linear 13-amino acid structure and the pharmacokinetic profile observed in Phase 1 data are consistent with peripheral distribution rather than CNS penetration. This is a key structural distinction from Melanotan II's cyclic architecture, which enables blood-brain barrier crossing. Tissue distribution concentrates the compound's activity in peripheral tissues, particularly melanocyte-rich skin.

Half-Life The measured half-life from the Dorr et al. Phase 1 study is approximately 0.8-1.7 hours , directly measured in humans via multiple sampling points across subcutaneous, intravenous, and oral administration arms. This short half-life is what drove the development of the slow-release 16 mg implant formulation for clinical use.

Metabolism & Elimination Clearance values from Phase 1 data: 0.12-0.19 L/kg/h. Like native alpha-MSH, MT-1 is metabolized primarily through proteolytic cleavage (enzymatic breakdown of the peptide chain). The structural modifications at positions 4 and 7 substantially extend active lifetime compared to the native peptide, which has a half-life of only minutes in circulation.

Data gaps: The Dorr et al. Phase 1 pharmacokinetic study had an extremely small sample size (n=3). Tissue distribution data in humans is limited. CNS penetration has been characterized as absent based on structural analysis and peripheral pharmacokinetics rather than direct CNS measurement studies.

Mechanistic Research

MC1R-cAMP-MITF-Tyrosinase Cascade (Evidence: Human and animal , Hadley and Dorr, 2006)

MT-1 binding to MC1R triggers Galphas protein coupling, which activates adenylyl cyclase and elevates intracellular cAMP (cyclic AMP, the cellular chemical messenger). cAMP activates PKA (Protein Kinase A), which phosphorylates CREB (a gene-regulatory protein). CREB upregulates MITF , the master transcription factor for melanogenesis , which drives tyrosinase expression. Tyrosinase catalyzes the rate-limiting step in eumelanin synthesis. This cascade is the primary and best-characterized mechanism, confirmed across in vitro cell culture, animal models, and human tanning observations.

Nucleotide Excision Repair (NER) Enhancement (Evidence: Animal and in vitro)

The cAMP signal generated by MC1R activation appears to upregulate nucleotide excision repair (NER) , the cellular process that removes UV-induced DNA damage. The specific lesions targeted are cyclobutene pyrimidine dimers (CPDs, damaged DNA sections caused by UV-B light fusing adjacent DNA bases). These dimers are the primary mutagenic lesions caused by UV-B radiation and are implicated in skin cancer initiation. Enhanced NER capacity following MC1R activation reduces the mutagenic burden in melanocytes and keratinocytes, representing a separate photoprotective mechanism operating alongside physical UV absorption by melanin.

MC1R Redox Homeostasis Pathway (Evidence: Preliminary , post-2021 research)

Emerging research has identified MC1R as a participant in cellular redox homeostasis , the regulation of oxidative stress and antioxidant defenses (the balance between damaging free radicals and the molecules that neutralize them). MT-1's MC1R activation appears to engage antioxidant processes that may extend protective effects beyond pigmentation. This pathway has been proposed as mechanistically relevant in neural tissue as well, though direct evidence in human neural contexts is absent.

Anti-Inflammatory Signaling via Peripheral MC1R (Evidence: Animal and early human)

MC1R is expressed on macrophages, monocytes, T-cells, keratinocytes, and fibroblasts in addition to melanocytes. MT-1 activation of MC1R on these immune and structural cells suppresses pro-inflammatory cytokines including IL-1, inhibits neutrophil migration, and reduces inflammatory signaling in peripheral tissue. MC1R-deficient mouse models demonstrated that these anti-inflammatory effects are absent without functional MC1R , confirming the receptor's necessary role in this pathway rather than treating these observations as coincidental.

Condition-Focused Research

Erythropoietic Protoporphyria (EPP) {#research-epp}

Three Phase 3 randomized controlled trials enrolled a total of 244 adults with EPP and compared 16 mg afamelanotide subcutaneous implants to placebo. Primary endpoints measured pain-free sun exposure time and patient-reported quality of life. Treated patients achieved statistically significant and clinically meaningful increases in outdoor sun exposure tolerance compared to placebo, with reductions in phototoxic pain episodes. Safety monitoring across the trial program showed no increase in melanoma incidence, with mild hyperpigmentation in 33% of subjects and nevi formation in 4% vs. 2% placebo. These trials formed the basis for FDA approval of Scenesse in 2019. (Evidence: Strong , Langendonk et al., 2015, NEJM)

UV Photoprotection and Sunburn Cell Reduction {#research-photoprotection}

A Phase 1 UV-B synergy study (n=8, 2004) administered MT-1 at 0.08 mg/kg subcutaneously for 10 days combined with UV-B irradiation at 3 times the minimal erythema dose (the threshold UV level that produces just-visible redness). Tanning was observed in 3 of 4 MT-1 subjects, with a 47% reduction in sunburn cells compared to controls. A separate Phase 1 sunlight tanning study found that approximately 50% less sun exposure was required to achieve equivalent tanning compared to controls, with tanning sustained for more than three weeks post-dosing. Both studies had small sample sizes, limiting the strength of conclusions, though the direction of effect is consistent with the mechanism. (Evidence: Moderate , Phase 1 human data)

Photodynamic Therapy (PDT) Phototoxicity Reduction {#research-pdt}

Phase 2 trials examined MT-1's ability to reduce phototoxic side effects in patients undergoing photodynamic therapy for skin conditions. Results from approximately 2004 showed reduced phototoxicity and improved sunlight tolerance in treated subjects. A secondary finding across Phase 2 PDT trials was improved mood and outlook in treated participants , attributed to MT-1's effect rather than the PDT procedure itself, though the mechanism was not fully characterized. Detailed peer-reviewed results from these Phase 2 trials are limited in the publicly available literature. (Evidence: Moderate , Phase 2 human data)

Polymorphic Light Eruption (PLE) {#research-ple}

Phase 3 trials in PLE have been conducted, with PLE representing a logical extension of MT-1's photoprotective mechanism into one of the most prevalent UV-related skin conditions in temperate climates. Full peer-reviewed results are not comprehensively available in the published literature as of this guide's update date. No regulatory approval has been granted for this indication to date, making it a research indication with Phase 3 evidence pending full publication. (Evidence: Moderate , Phase 3 trials conducted; full published results limited)

Vitiligo {#research-vitiligo}

A randomized multicenter trial examined afamelanotide in combination with narrowband UV-B phototherapy for vitiligo , a condition characterized by loss of melanocytes and pigmentation in patches of skin. The rationale is that afamelanotide's MC1R stimulation may support repigmentation of affected areas when combined with the UV trigger that activates surviving melanocytes. Results showed repigmentation benefit in the combination arm compared to phototherapy alone in certain skin types. (Evidence: Moderate , Lim et al., 2015, JAMA Dermatology)

Safety & Tolerability Research

Across the Phase 1, Phase 2, and Phase 3 clinical trial program, MT-1 has shown a consistent and contained safety profile. Phase 1 data established nausea and flushing as the primary acute side effects. Phase 3 EPP trials in 244 adults confirmed mild hyperpigmentation in 33% of subjects and nevi formation at a slightly elevated rate (4% vs. 2% placebo), neither of which was associated with serious outcomes. Critically, no increase in melanoma incidence was observed across the trial program despite sustained MC1R stimulation of melanocyte activity. The EPP trial program , involving repeated implant cycles across multiple seasons , represents the most rigorous and longest-duration human tolerability dataset available for any melanocortin peptide.

Research Limitations

MT-1's research limitations are somewhat unusual compared to most research peptides , the gaps here are not a wholesale absence of human data, but specific holes in what has been published and characterized. The Dorr et al. Phase 1 pharmacokinetic study had only three subjects, meaning pharmacokinetic parameters carry wide confidence intervals despite being directly measured in humans. At least one confirmed non-responder appeared in Phase 1 tanning data, but MC1R genotyping was not systematically performed across study populations, leaving the genetic determinants of response poorly characterized. Phase 2 PDT and PLE trial results are not fully published in peer-reviewed form, meaning a portion of the clinical dataset exists only in regulatory filings or conference presentations. Post-2021 research on MC1R redox homeostasis and neuroprotective mechanisms is entirely preclinical, with no direct human confirmation. The significance of the nevi formation signal (4% vs. 2% placebo in Phase 3 EPP trials) remains incompletely characterized in terms of long-term implications.

Is Melanotan I Legal? Regulatory & Sports Status

FDA status: Afamelanotide (Scenesse, 16 mg subcutaneous implant) is FDA-approved for the treatment of erythropoietic protoporphyria (EPP) in adults. This approval, granted in 2019, represents the only FDA-approved medication in the melanocortin peptide class for a photoprotective or dermatological indication. Outside this specific indication and formulation, MT-1 is not approved for human use in the United States. Access to the approved Scenesse formulation requires a prescription and enrollment through the Scenesse REMS (Risk Evaluation and Mitigation Strategy) program.

Research Use Only (RUO): Outside the FDA-approved EPP indication, MT-1 is classified as a research compound in most jurisdictions. This means it is available for laboratory and research purposes but is not authorized for general human use without a prescription and the specific medical indication that supports prescribing.

WADA / USADA status: As of March 2026, Melanotan I is not listed on the WADA prohibited list. It does not appear under any current prohibited category. Athletes subject to anti-doping testing should verify current WADA list status independently before use, as the prohibited list is updated annually and this status can change.

Country-specific notes: The European Medicines Agency (EMA) has also approved afamelanotide (Scenesse) for EPP, making it available by prescription in European Union member states for the same indication. In Australia, afamelanotide has been available under the Therapeutic Goods Administration (TGA) framework. In the United Kingdom, regulatory status post-Brexit should be verified independently. In jurisdictions without approved access to Scenesse, research-grade MT-1 is treated comparably to other research peptides , available for non-clinical research but not for human therapeutic use.

Detection: No specific anti-doping test for Melanotan I is currently in routine use in sports anti-doping programs. Given its non-prohibited status, detection methodology has not been a priority development area for anti-doping agencies.

Melanotan I vs. Alternatives

Commonly Paired With , Synergistic Stacks

• Melanotan I + BPC-157: Some users in tracked protocols combine MT-1 with BPC-157 when using MT-1 for its anti-inflammatory and skin-repair properties alongside tissue recovery goals. The combination is based on their complementary anti-inflammatory mechanisms , MT-1 via MC1R peripherally, BPC-157 via separate pathways , rather than any documented synergistic tanning effect. No published combination data exists.
• Melanotan I + GHK-Cu: GHK-Cu (copper peptide) is used for skin repair, collagen synthesis, and anti-aging applications. Some tracked protocols combine it with MT-1 when both pigmentation and skin quality outcomes are the goal. The two compounds work through entirely separate mechanisms with no known interaction. Evidence for the combination is anecdotal.

Alternatives , When Another Peptide May Be Considered

Melanotan II (MT-2) MT-2 is the most common point of comparison for Melanotan I and the compound most people encounter first when searching for tanning peptides. MT-2 produces tanning through the same core MC1R mechanism but also activates MC3R and MC4R , driving sexual function effects (spontaneous erections in men, increased libido), appetite suppression, and CNS activity that MT-1 does not produce. Someone who specifically wants only the tanning and photoprotective effects without the CNS and sexual side effects would favor MT-1. Someone comfortable with , or specifically seeking , MT-2's broader effects would choose differently.

PT-141 (Bremelanotide) PT-141 is a melanocortin peptide derived from the same University of Arizona research program as MT-1 and MT-2, but developed specifically for sexual dysfunction via its MC4R activity. It does not meaningfully stimulate tanning. It is relevant to this comparison only in the sense of being a different application within the melanocortin peptide family , someone researching MT-1 for tanning or photoprotection would not consider PT-141 an alternative for those goals. It received FDA approval for hypoactive sexual desire disorder in premenopausal women in 2019.

GHK-Cu (Copper Peptide) For users whose primary interest in MT-1 is skin quality, repair, and anti-aging rather than tanning specifically, GHK-Cu is a meaningful alternative with a distinct mechanism (collagen induction, growth factor modulation, tissue repair) and a different evidence base. GHK-Cu has more documented topical application data than MT-1.

Comparison table:

Build Your Melanotan I Peptide Protocol

FAQs

What is Melanotan I?

Melanotan I (MT-1), also known as afamelanotide, is a synthetic 13-amino acid analog of alpha-melanocyte-stimulating hormone (alpha-MSH) originally developed at the University of Arizona in the 1980s. It is the only FDA-approved compound in the melanocortin peptide class, marketed as Scenesse for erythropoietic protoporphyria (EPP) , a rare and painful photosensitivity disorder. Outside its approved indication, it is studied and used as a research compound for tanning, UV photoprotection, and anti-inflammatory effects.

What does Melanotan I do?

MT-1 primarily stimulates the production of eumelanin , the brown-black skin pigment that provides UV protection , by activating the MC1R receptor on melanocytes, the pigment-producing cells in the skin. This produces skin tanning without requiring UV light to trigger it and increases the skin's natural resistance to UV-induced damage. It also has documented anti-inflammatory effects via MC1R activation on immune cells in skin tissue.

How long does Melanotan I take to work?

In injection-based Phase 1 research studies, visible skin darkening was typically first observed within the first 3-7 days of daily subcutaneous dosing, with progressive tanning continuing through the 10-day study periods. Tanning was noted to persist for more than three weeks after dosing ended in Phase 1 sunlight studies. For EPP patients using the Scenesse implant, meaningful increases in sun tolerance are observed within the first treatment cycle.

What is the typical dose of Melanotan I?

Published Phase 1 and Phase 2 research studied a range of subcutaneous doses, with the evidence base spanning from early pharmacokinetic work through larger photoprotection trials. The FDA-approved Scenesse formulation for EPP uses a fixed 16 mg subcutaneous implant placed approximately every two months, which releases slowly over 30 days. Protocols outside the EPP indication vary by goal and individual response , MyPeptidePal builds personalized protocols based on your specific situation.

Is Melanotan I legal?

Melanotan I as afamelanotide (Scenesse) is FDA-approved and legally available by prescription in the United States for erythropoietic protoporphyria. Outside this specific indication, research-grade MT-1 is classified as a research compound in most jurisdictions and is not approved for general human use. It is not currently on the WADA prohibited list. Regulatory status varies by country , users are responsible for understanding the rules in their location.

Can Melanotan I be taken orally?

No , oral administration is not a viable route for MT-1. The 1997 Phase 1 pharmacokinetic study evaluated oral delivery and confirmed substantially inferior bioavailability compared to subcutaneous injection, consistent with the gastric and enzymatic degradation that affects most peptides when swallowed. No oral formulation of MT-1 has been developed or studied for clinical use, and subcutaneous injection (or the slow-release implant for EPP) are the only practically supported routes.

What is the difference between Melanotan I and Melanotan II?

The most important difference is receptor selectivity. MT-1 selectively activates MC1R, producing focused tanning and photoprotective effects with minimal CNS involvement. MT-2 activates MC1R plus MC3R and MC4R , receptors in the hypothalamus and central nervous system , producing additional effects including sexual arousal, spontaneous erections in men, and appetite suppression that MT-1 does not produce at therapeutic doses. MT-1 has an FDA-approved indication; MT-2 never received regulatory approval. Structurally, MT-1 is a linear 13-amino acid peptide while MT-2 is a cyclic 7-amino acid peptide.

Does Melanotan I cause sexual side effects like Melanotan II?

No , sexual side effects are not part of MT-1's profile in clinical research. MT-2 produces sexual function effects (spontaneous erections, increased libido) because it activates MC4R receptors in the central nervous system. MT-1's linear structure does not readily cross the blood-brain barrier, and its receptor profile is focused on MC1R rather than the CNS-active MC3R and MC4R receptors responsible for MT-2's sexual effects. This receptor selectivity difference is the primary clinical reason the two compounds are used for entirely different purposes.

Does Melanotan I work for everyone?

No , not everyone responds to MT-1. Phase 1 data documented at least one subject who showed zero pigmentation response despite receiving a standard dose. The most likely explanation is a loss-of-function variant in the MC1R gene , the same genetic variation associated with fair skin, red hair, and impaired natural tanning ability. Individuals with certain MC1R polymorphisms may produce predominantly pheomelanin regardless of MC1R stimulation, and their response to MT-1 may be absent or substantially reduced. MC1R genetic status has not been systematically characterized across trial populations, which represents an ongoing research gap.

What does research-grade Melanotan I look like once reconstituted?

Melanotan I dissolves into a clear, colorless to very slightly pale solution after reconstitution. Significant cloudiness, visible particles, chunks in the solution, or discoloration , including yellowing or browning , indicate potential degradation or quality issues and mean the compound should not be used. MT-1's Position 4 modification (norleucine substitution) exists specifically to resist oxidative degradation, but poor manufacturing or improper storage can still compromise the compound before it is used.

Final Thoughts

Melanotan I occupies a genuinely unusual position in the peptide research landscape. It is the one melanocortin compound that completed the full journey from university laboratory to FDA approval , three Phase 3 clinical trials, 244 adults, and a regulatory decision that confirmed both its efficacy for EPP and a safety profile that held up under rigorous scrutiny. For anyone researching peptides in this class, that track record matters. The EPP indication is narrow, and the lives it has changed belong to people with a rare and painful condition. But the mechanism behind it , targeted MC1R activation driving eumelanin synthesis, UV photoprotection, and anti-inflammatory signaling , is a well-characterized piece of biology that extends to broader questions about skin resilience, UV resistance, and photosensitivity.

The research picture outside the EPP approval is more mixed. Phase 1 and Phase 2 data on tanning and photoprotection are real and encouraging, but they come from small studies. The Phase 3 PLE program represents a significant expansion of the evidence base, but full published results are not yet comprehensively available. The emerging neuroprotective and redox biology angles are interesting but early , there is a difference between a plausible mechanistic hypothesis and confirmed clinical evidence, and it is worth keeping that line clear when evaluating MT-1's potential. The receptor selectivity advantage over MT-2 is unambiguous and clinically meaningful , MT-1's focus on MC1R produces tanning and photoprotective outcomes without the CNS-mediated sexual and appetite effects that complicated MT-2's development.

If you are exploring Melanotan I for photoprotection, skin resilience, or understanding where your goals align with what the research supports, the starting point is knowing exactly what you are working with , your skin type, your MC1R response potential, your cycle goals, and how MT-1 fits within the broader picture of your protocol. That is the kind of specificity a general guide cannot provide but a personalized protocol can. MyPeptidePal is built to take you from the broad research picture this guide covers to a protocol that is actually calibrated to your situation.

References

1. Langendonk, J. G., Balwani, M., Anderson, K. E., Bonkovsky, H. L., Anstey, A. V., Bissell, D. M., Bloomer, J., Edwards, C., Neumann, N. J., Parker, C., Phillips, J. D., Lim, H. W., Hamzavi, I., Wayne Grady, R., Kauppinen, R., Naik, H., & Desnick, R. J. (2015). Afamelanotide for erythropoietic protoporphyria. New England Journal of Medicine, 373(1), 48–59.

2. Hadley, M. E., & Dorr, R. T. (2006). Melanocortin peptide therapeutics: Historical milestones, clinical studies and commercialization. Peptides, 27(4), 921–930.

3. Lim, H. W., Grimes, P. E., Agbai, O., Hamzavi, I., Henderson, M., Hasan, S., & Pandya, A. G. (2015). Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: A randomized multicenter trial. JAMA Dermatology, 151(1), 42–50.

4. ClinicalTrials.gov. (n.d.). Afamelanotide for erythropoietic protoporphyria (NCT00946961). U.S. National Library of Medicine.

5. Dorr, R. T., Ertl, G., Levine, N., Brooks, C., Bangert, J. L., Powell, M. B., Alberts, D. S., & Hadley, M. E. (1996). Effects of a superpotent melanotropic peptide in combination with solar UV radiation on tanning of the skin in human volunteers. Archives of Dermatology, 132(10), 1164–1168.

Additional sources pending editorial review , the 1997 Phase 1 pharmacokinetic study (Dorr et al., multi-route PK characterization: SC, IV, oral; half-life 0.8-1.7 hours; clearance 0.12-0.19 L/kg/h), the Phase 1 UV-B synergy study (EpiTan Ltd, 2004, n=8, 47% sunburn cell reduction), and Phase 2 EpiTan PDT and photoprotection study data referenced in this article exist in regulatory filings and conference presentations rather than fully indexed peer-reviewed publications at the time of this guide's preparation.